Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors

被引:21
|
作者
Villa, Juan Antonio [1 ,2 ]
Pike, Daniel P. [1 ,2 ]
Patel, Kunjan B. [1 ,2 ]
Lomonosova, Elena [1 ,2 ]
Lu, Gaofeng [1 ,2 ,3 ]
Abdulqader, Roz [1 ,2 ]
Tavis, John E. [1 ,2 ]
机构
[1] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA
[2] St Louis Univ, Sch Med, St Louis Univ Liver Ctr, St Louis, MO 63104 USA
[3] Zhengzhou Univ, Affiliated Hosp 2, Dept Gastroenterol, Zhengzhou, Henan, Peoples R China
关键词
Hepatitis B virus; DNA virus; RNA processing; Ribonuclease; Endoribonuclease; STRAND DNA-SYNTHESIS; RNASE-H; REVERSE-TRANSCRIPTASE; RNA/DNA HYBRID; VIRAL-DNA; HIV-1; RT; POLYMERASE; REPLICATION; DOMAIN; EXPRESSION;
D O I
10.1016/j.antiviral.2016.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatitis B virus (HBV) reverse transcription requires coordinated function of the reverse transcriptase and ribonuclease H (RNaseH) activities of the viral polymerase protein. The reverse transcriptase has been biochemically characterized, but technical difficulties have prevented both assessment of the RNaseH and development of high throughput inhibitor screens against the RNaseH. Expressing the HBV RNaseH domain with both maltose binding protein and hexahistidine tags led to stable, high-level accumulation of the RNaseH in bacteria. Nickel-affinity purification in the presence of Mg2+ and ATP removed co-purifying bacterial chaperones and yielded nearly pure monomeric recombinant enzyme. The endonucleolytic RNaseH activity required an DNA:RNA duplex >= 14 nt, could not tolerate a stem-loop in either the RNA or DNA strands, and could tolerate a nick in the DNA strand but not a gap. The RNaseH had no obvious sequence specificity or positional dependence within the RNA, and it cut the RNA at multiple positions even within the minimal 14 nt duplex. The RNaseH also possesses a processive 3'-5' exoribonuclease activity that is slower than the endonucleolytic reaction. These results are consistent with the HBV reverse transcription mechanism that features an initial endoribonucleolytic cut, 3'-5' degradation of RNA, and a sequence-independent terminal RNA cleavage. These data provide support for ongoing anti-RNaseH drug discovery efforts. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:186 / 195
页数:10
相关论文
共 50 条
  • [21] Entry of hepatitis B virus: Mechanism and new therapeutic target
    Xie, Y.
    Zhai, J.
    Deng, Q.
    Tiollais, P.
    Wang, Y.
    Zhao, M.
    PATHOLOGIE BIOLOGIE, 2010, 58 (04): : 301 - 307
  • [22] Hepatitis B and C virus antiviral resistance
    Saez-Lopez, Ana
    Aguero-Balbin, Jesus
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (09): : 576 - 584
  • [23] Hydroxylated Tropolones Inhibit Hepatitis B Virus Replication by Blocking Viral Ribonuclease H Activity
    Lu, Gaofeng
    Lomonosova, Elena
    Cheng, Xiaohong
    Moran, Eileen A.
    Meyers, Marvin J.
    Le Grice, Stuart F. J.
    Thomas, Craig J.
    Jiang, Jian-kang
    Meck, Christine
    Hirsch, Danielle R.
    D'Erasmo, Michael P.
    Suyabatmaz, Duygu M.
    Murelli, Ryan P.
    Tavis, John E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1070 - 1079
  • [24] New insights into hepatitis B virus biology and implications for novel antiviral strategies
    Chen, Jieliang
    Wu, Min
    Liu, Kuancheng
    Zhang, Wen
    Li, Yaming
    Zhou, Xiaohui
    Bai, Lu
    Yuan, Zhenghong
    NATIONAL SCIENCE REVIEW, 2015, 2 (03) : 296 - 313
  • [25] New insights into hepatitis B virus biology and implications for novel antiviral strategies
    Jieliang Chen
    Min Wu
    Kuancheng Liu
    Wen Zhang
    Yaming Li
    Xiaohui Zhou
    Lu Bai
    Zhenghong Yuan
    National Science Review, 2015, 2 (03) : 296 - 313
  • [26] The search for a new endpoint for antiviral prophylaxis in hepatitis B virus transplanted patients
    Shouval, Daniel
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (08) : 537 - 538
  • [27] Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection
    Qaqish, RB
    Mattes, KA
    Ritchie, DJ
    CLINICAL THERAPEUTICS, 2003, 25 (12) : 3084 - 3099
  • [28] Antiviral therapy for hepatitis B virus infections: new targets and technical challenges
    Feld, J
    Locarnini, S
    JOURNAL OF CLINICAL VIROLOGY, 2002, 25 (03) : 267 - 283
  • [29] Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development
    Clark, Daniel N.
    Hu, Jianming
    ANTIVIRAL RESEARCH, 2015, 123 : 132 - 137
  • [30] Glucosidase inhibitors as antiviral agents for hepatitis B and C
    Durantel, David
    Alotte, Christine
    Zoulim, Fabien
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 125 - 129